Cost Savings Using a Protocol Approach to Manage Anemia in a Hemodialysis Unit
| Autor: | Emily C. Charlesworth, Robert M. Richardson, Marisa Battistella |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty Darbepoetin alfa Anemia Iron medicine.medical_treatment Drug Costs Hemoglobins Clinical Protocols Cost Savings Renal Dialysis hemic and lymphatic diseases medicine Humans Intensive care medicine Erythropoietin Aged Retrospective Studies Protocol (science) biology business.industry Transferrin saturation Transferrin Middle Aged medicine.disease Ferritin Hemodialysis Units Hospital Nephrology Ferritins Hematinics biology.protein Kidney Failure Chronic Female Hemoglobin Hemodialysis Deprescribing business medicine.drug |
| Zdroj: | American Journal of Nephrology. 39:509-514 |
| ISSN: | 1421-9670 0250-8095 |
| Popis: | Background: National guidelines recommend using anemia management protocols to guide treatment. The objective of this study was to determine if an anemia management protocol would improve hemoglobin (Hgb) indices in hemodialysis patients and to measure whether the protocol would reduce the use and cost of darbepoetin alfa (DBO) and intravenous (IV) iron in hemodialysis patients. Methods: An anemia management protocol was created and implemented for hemodialysis patients at our institution. A retrospective observational review of the use of DBO and IV iron as well as changes in Hgb, transferrin saturation and ferritin in 174 patients was conducted 6 months before and after implementation of the anemia protocol. Results: The number of Hgb measurements in the target range increased from 44.3 to 46.0% (p = 0.48) after protocol implementation. The mean weekly dose of DBO was reduced from 34.56 ± 31.12 to 31.11 ± 28.64 μg post-protocol implementation (p = 0.011), which translated to a cost savings of USD 41,649 over 6 months. The mean monthly IV iron dose also decreased from 139.56 ± 98.83 to 97.65 ± 79.05 mg (p < 0.005), a cost savings of USD 18,594 over the same time period. Conclusion: The use of an anemia management protocol resulted in the deprescribing of DBO and iron agents while increasing the number of patients in the target Hgb range, which led to significant cost savings in the treatment of anemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|